Abstract
Background and Purpose: Bleomycin (BLM), one of the most common sclerosants, is often used to treat venous malformations (VMs). The present study was designed to investigate whether endothelial mesenchymal transition (EndoMT) contributes to the therapeutic effects ofBLM.Experimental Approach: Endothelial and mesenchymal markers of HUVECs were measured by immunofluorescence, real‐time quantitative PCR and Western blot analysis. Cell migration and tube formation assays were performed to evaluate endothelial cell function. Slug small‐interferingRNAand specific inhibitors [Z‐VAD‐FMK for pan caspases, rapamycin for mammalian target of rapamycin (mTOR)] were used to investigate the mechanism.Key Results: Long term (48 h or longer) treatment withBLM(0.1 mU·mL−1) inducedEndoMTinHUVECs, as manifested by a reduction in the expression of vascular endothelial‐cadherin and an up‐regulation in the expression of α‐smooth muscle actin and fibroblast specific protein‐1, as well as activation of the transcription factor Slug. The size and protein content of the transformed cells were increased. BLM also enhanced the migration of HUVECs but diminished their tube formation. By employing rapamycin, we demonstrated that activation of the mTORpathway is involved inBLM‐inducedEndoMTinHUVECs.Conclusions and Implications: Our results show that a Slug‐dependentEndoMTprocess is involved inBLM‐induced therapeutic effects on endothelial cells and, more importantly, indicate the potential role of this process in the sclerotherapy ofVMs.

This publication has 40 references indexed in Scilit: